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ABSTRACT
Context: The prevalence of hypertension in developing
countries is coming closer to values found in developed
countries. However, surveys usually rely on readings taken
at a single visit, the option to implement the diagnosis on
readings taken at multiple visits, being limited by costs.
Objective: To estimate more accurately the magnitude
and extent of the resource that should be allocated to the
prevention of hypertension.
Design: Population-based cross-sectional survey with
triplicate blood pressure (BP) readings taken on two
separate home-visits.
Setting: Rural and urban locations in three areas of
Yemen (capital, inland and coast).
Participants: A nationally representative sample of the
Yemen population aged 15–69 years (5063 men and
5179 women), with an overall response rate of 92% in
urban and 94% in rural locations.
Main outcome measure: Hypertension diagnosed as
systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg
and/or self-reported use of antihypertensive drugs.
Results: Hypertension prevalence (age-standardised to
the WHO world population 2001) based on fulfilling the
same criteria on both visits (11.3%; 95% Cl 10.7% to
11.9%), was 35% lower than estimation based on the
first visit (17.3%; 16.5% to 18.0%). Advanced age,
blood glucose ≥7 mmol/l or proteinuria ≥1+ at dipstick
test at visit one were significant predictors of
confirmation at visit 2. The 959 participants found to be
hypertensive at visit 1 or at visit 2 only and thus excluded
from the final diagnosis had a rate of proteinuria (5.0%;
3.8% to 6.5%) comparable to rates of the general
population (6.1%; 5.6% to 6.6%), and of subjects
normotensive at both visits (5.6%; 5.1% to 6.2%). Only
1.9% of Yemen population classified at high or very high
cardiovascular (CV) risk at visit 1 moved to average, low
or moderate CV risk categories after two visits.
Conclusions: Hypertension prevalence based on
readings obtained after two visits is 35% lower than
estimation based on the first visit, subjects were excluded
from final diagnosis belonging to low CV risk classes.
INTRODUCTION
The WHO has been indicating since 2001
that cardiovascular (CV) disease is the first
cause of death worldwide.1 More precisely,
ARTICLE SUMMARY
Article focus
▪ To investigate the effects on healthcare resource
allocation decision making of taking blood pres-
sure at one or two visits with cardiovascular risk
stratification.
▪ To identify the characteristics of subjects who
are excluded from the final diagnosis when
restricting the diagnostic criteria.
Key messages
▪ The present study clarify that although there is a
large discrepancy (35%) in the estimation of
hypertension prevalence on the basis of one visit
or two visits, only 1.9% of subjects classified at
high or very high cardiovascular (CV) risk at visit
1 moved to average, low or moderate CV risk
categories after two visits.
▪ Subjects excluded from the final diagnosis of
hypertension, had rates of proteinuria and self-
reported CV disease comparable with normoten-
sive subjects and the general population.
▪ According to present data the choice of one or
two visits is not relevant when a strategy that
allows for a more comprehensive framework of
CV risk is implemented.
Strenght and limitations of this study
▪ This study utilised data from nationally representa-
tive survey conducted with a door-to-door approach
and a high response level in a developing country.
▪ Laboratory investigations were performed with
the use of dry chemistry. However, the long dis-
tance to get to a service laboratory requires ship-
ments under special conditions, often resulting in
deterioration and spoilage of the specimen.
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80% of CV death are now occurring in low-income and
middle-income countries.2 3 Surveys performed in devel-
oping countries are revealing that changing lifestyle and
urbanisation are associated with growing prevalence of
hypertension4 which is coming closer to values found in
developed countries.5 All these surveys rely on readings
taken at a single visit, the option to implement the diag-
nosis on readings taken at multiple visits, as recom-
mended by guidelines for clinical practice,6 7 being
limited due to costs. Diagnostic criteria based on read-
ings collected at a single visit, might, however, lead to
include subjects with high blood pressure (BP) variabil-
ity and episodic hypertension, with a final overestimation
of hypertension prevalence.8 9 Although high BP vari-
ability potentially increases the risk of future CV
events,10 treatment decision is uncertain. Conversely,
resource allocation in developing countries requires
sound data. Finally, although the association between
hypertension and target organ damage was recently
reported to be independent by the diagnostic criteria,9
the CV risk characteristics of subjects which are
impacted more from the two survey strategies, being
either included among hypertensives after a single visit
survey or excluded when restricting the diagnostic cri-
teria, is currently unknown.
In the Hypertension and Diabetes in Yemen (HYDY)
survey, subjects received urine dipstick test for protein-
uria combined with triplicate BP readings performed
during two separate home-visits as recommended by
guidelines for the clinical diagnosis of hypertension.6 7
To estimate more accurately the magnitude and extent
of the resource that should be allocated to the preven-
tion of hypertension we (1) compared prevalence,
awareness, treatment and control rates, and CV risk
stratification when the definition of hypertension rely on
data collected either at a single or at two visits carried
out in different dates and (2) identified the characteris-
tics of subjects who are excluded from the final diagno-
sis when restricting the diagnostic criteria.
METHODS
Study sites and study population
The Yemen population was estimated to be more than 21
million in 2007.11 A multistage stratified sampling
method was used. In the first stage, Yemen was stratified
into three regions, the capital area, the inland and the
coastal area. In addition to the governorate of Sana’a, the
governorate of Taizz in the inland, and the governorates
of Al Hudaydah and Hadramaut on the coast were
selected to be representative of the geographic,
economic and climatic characteristics of the country. In
the second stage, rural and city regions were identified
from each study area. In the third stage, districts were
arbitrarily identified within each urban and rural region,
boundaries being defined using local maps or in consult-
ation with the local health workers. The total number of
districts within each study area (20 in the capital area, 12
in the inland and 8 in the coastal area) was proportional
to the estimated population size of the area. In the final
stage, due to the lack of a national population register, a
cluster of 300 participants was made for each district, par-
ticipants being equally allocated by gender and age-group
(6–14, 15–24, 25–34, 35–44, 45–54 and 55–69 years) to
a total of 12 strata. All male and female subjects aged
6–69 years who lived permanently in the study areas
were eligible. Pregnant women were excluded. A
common set of rules for making a cluster was followed.
Briefly, a sampling frame was established following enu-
meration of houses counting from the centre to the
suburbs of the district and the first house to be surveyed
was chosen at random by choosing a number on the list
and selecting the corresponding house. Investigators
then continued to call at every second address, always
turning left. A household was defined as a group of
people who usually live under the same roof and share
meals. If more than one household was present in the
same dwelling one was randomly selected. All of the
eligible subjects in the same household were invited to
take part in the study. About 182 subjects refused to
participate, and 12 257 were evaluated between February
2008 and March 2009. Results obtained in subjects aged
≥15 years (5063 men and 5179 women) are reported in
the present study.
The study was approved by the Ethical Committee of
the University of Science and Technology, Sana’a,
Yemen (Ref. 1–2007). Districts Leaders and local Chiefs
also consented to the survey. Informed consent was
obtained from every participant before data collection.
No incentives were offered to study participants.
Participants with untreated conditions identified during
the examination were referred to a primary healthcare
provider.
Data collection
The survey was performed following the three different
levels of the WHO Stepwise Approach to Chronic
Disease Risk Factor Surveillance (STEPS),12 which
included questionnaire, physical measurements and bio-
chemical measurements, using standardised methods.
The burden of hypertension in the population was
assessed by taking triplicate BP measurements on two
visits, separated by few days. Data collection was con-
ducted at home by centrally trained survey teams com-
posed by two investigators of the opposite gender.
Community sensitisation activities preceded each
survey round, including local council briefings with the
chiefs and elders of the villages. During the first visit
(visit 1) the head of the household or spouse and the
participant were informed about the objectives, and pro-
cedural details of the survey. Privacy of information was
assured. After obtaining consent, a study questionnaire
was administered. The study questionnaire included
questions about demographics, lifestyle and medical
history (WHO STEPS-Instrument V.2.0).12 Participants
were asked if they had been advised to change their diet
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(‘special prescribed diet’), or to lose weight (‘advice or
treatment to lose weight’), or quit smoking (‘advice or
treatment to stop smoking’) or do exercise (‘advice
to start or do more exercise’) attributed to hypertension,
by indication of a health professional. Close-ended ques-
tions were asked to find out if they had been seen by a
traditional healer over the last year or if they had been
using herbal or traditional remedies attributed to high
BP. ‘Known ischaemic heart disease’ (IHD) was defined
as a person with a history of heart attack requiring hospi-
talisation, or a person with physician-diagnosed IHD who
was taking medication as confirmed by the survey team.
‘Known stroke’ was defined as a person with a history of
abrupt-onset weakness or paralysis on one side of the
body, with or without a history of hospitalisation, or a
person with physician-diagnosed stroke and currently
experiencing weakness or paralysis on one side of the
body.
The mid-arm circumference was measured to use the
appropriate cuff size (small, medium and large for
mid-arm circumferences of 17–22, 22–32 and 32–42 cm,
respectively). Three measurements of BP and pulse rate
were taken at 2 min intervals on the dominant arm after
a rest of at least 15 min, in the seated position.7 Readings
were obtained using a clinically validated semiautomatic
sphygmomanometer (HEM 705 IT; Omron Matsusaka
Co Ltd, Japan). The average of the last two readings for
systolic and diastolic BP was defined as SBP1 and DBP1,
respectively. Anthropometric measurements were taken
on standing participants wearing light clothes and
without shoes using standard techniques.13 Body weight
was measured to the nearest 0.1 kg using a spring balance
and height to the nearest 0.5 cm using a stadiometer.
Waist and hip circumference was measured to the nearest
0.1 cm. Finger-prick blood samples were then obtained
from fasting (>8 h) subjects (aged ≥15 years) to measure
glucose (Accutrend system, Roche Diagnostics,
Mannheim, Germany), cholesterol and triglycerides
blood values (MultiCare-in, HPS, Italy) using dry chemis-
try. The subject was then asked to void. A midstream spe-
cimen of urine was collected and dipstick test (Auction
sticks, A.Menarini Diagnostics, Italy) was immediately per-
formed and read manually to semiquantitate the occult
blood (trace, 1+ to 4+) and protein (trace, 1+ to 4+). A
new appointment was taken for non-fasting participants
and for subjects who were menstruating. All subjects were
then visited again within the next 10 days by the same
survey team using the same measurement devices and
procedures for the second session of BP (SBP2 and
DBP2) and fasting glucose (FG2) measurements.
Diagnostic criteria
Arterial hypertension was defined as (1) systolic
BP≥140 mmHg and/or diastolic BP≥90 mmHg and/or
(2) self-reported use of antihypertensive drugs at the time
of the interview.7 More precisely, the prevalence of hyper-
tension was based on values measured at the first visit
(SBP1 and DBP1), at the second visit (SBP2 and DBP2)
and on fulfilling the same criteria for hypertension on
both visits. Awareness of hypertension was defined as self-
report of any prior diagnosis of hypertension by a health-
care professional among the population defined as having
hypertension. Hypertension treatment was defined as a
self-reported use of antihypertensive drugs within the
2 weeks preceding the interview. Hypertension control
was defined as systolic BP<140 mmHg and diastolic
BP<90 mmHg. The proportion of hypertension control
was relative to hypertensive treated with drugs.
Diabetes mellitus (DM) was defined as (1) FG
≥7.0 mmol/l at the two visits or (2) self-reported use of
hypoglycaemic medications at the time of the interview;
impaired FG (IFG) as FG≥5.6 mmol/l and <7.0 mmol/l
in the absence of hypoglycaemic medications; normal
FG as FG<5.6 mmol/l at the two visits.14 Overweight
and obesity were defined as a body mass index (BMI)
25.0–29.9 and ≥30 kg/m2, respectively. Abdominal
obesity was defined as waist circumference >102 cm in
men or >88 cm in women. Gender-specific tertiles for
BMI and waist-to-hip (W/H) ratio were calculated using
data of adult subjects without hypertension, normal FG,
cholesterol <5.0 mmol/l, triglycerides <1.7 mmol/l and
no protein at urine dipstick test. Resulting cut-offs were
20 and 23.2 kg/m2 for men and 20.5 and 24.3 kg/m2 for
women for BMI and 0.849 and 0.907 in men and 0.815
and 0.887 in women for W/H ratio. On the basis of
cholesterol and triglycerides assessments, subjects were
classified as high cholesterol (>5.0 mmol/l) or high tri-
glycerides (>1.7 mmol/l).7 15 Results of dipstick urinaly-
sis were classified as no protein (0), protein trace (±) or
proteinuria (≥+1). A smoker was defined as one who
smoked any form of tobacco on a daily (daily smoker)
or a non-daily (occasional smoker) basis. Those who had
smoked but had quit were designated as former
smokers, and those who had never smoked at all were
designated as never smokers. On the basis of education
level, subjects were classified into six levels: (1) illiterate,
(2) can read and write, (3) primary school, (4) prepara-
tory school, (5) secondary and (6) university or post.
Fruit and vegetable consumption were classified as (1)
≤1 day/week, (2) 2–4 day/week and (3) ≥5 days/week.
Participants were categorised as: sedentary if they
walked or cycled for less than 10 min daily, if their work
did not involve intense physical activity, and they did not
usually practice any sport or recreational physical activ-
ities; engaging in light-to-moderate physical activity if
they performed work or recreational physical activities 1
or 2 days/week; engaging in vigorous physical activity if
they performed work or recreational vigorous physical
activities 3 days or more/week.
According to the European Society of Hypertension/
European Society of Cardiology (ESH/ESC) chart7 risk
stratification (average, low, moderate, high and very high
added risk categories) was based on the presence of risk
factors (average of SBP1/SBP2 and DBP1/DBP2 graded
in five categories; age >55 years for men or >65 years for
women; daily smoking; waist circumference >102 cm in
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men or >88 cm in women; IFG; triglycerides >1.7 mmol/l;
total cholesterol >5.0 mmol/l), DM, subclinical organ
damage (protein trace at dipstick test) and established
renal (proteinuria ≥1+ at dipstick test) or CV disease
(self-reported stroke, myocardial infarction or peripheral
artery disease). The cluster of three of four risk factors
among abdominal obesity, altered fasting plasma
glucose, BP>130/85 mm Hg and high triglycerides (as
defined above) was considered as the presence of meta-
bolic syndrome.
Measures have been taken to attain complete reliabil-
ity and to reduce variation to reasonable limits. All study
personnel successfully completed the specific 1-week
training programme organised in Sana’a (December
2007) on the aims of the study and the specific methods
used to standardise the procedure for sampling and con-
tacting individuals, questionnaire administration and
form filling, BP measurements using electronic devices,
performing blood biochemical assay, performing urine
assay and data entry into computerised data base. The
training programme included a pilot testing performed
on a population sample of 400 individuals in urban and
rural areas of Sana’a.
Statistical methods
A sample size of at least 1117 subjects was required to
achieve a 1% precision around an estimated prevalence of
diabetes of 3% with 95% confidence level (Cl). Estimated
required sample size for two-sample comparison of dia-
betes prevalence of 2.25% versus 3.75% with the assump-
tion of 0.05 α (two-sided), 80% power, was 2161 subjects
for each group. Cleaning the data, handling missing data
and outliers were done according to the guidelines of
WHO for STEPS data management.12 Prevalence esti-
mates were calculated for the five age groups in the overall
population and by gender. Data are expressed as mean
±SD with 95% Cl for continuous variables, and as rates
with 95% CI for categorical variables. Prevalence was also
weighted to represent the total Yemen population aged
15–69 years (2008 estimated Yemen population),11 16 and
age standardised for age ranges 15–69 years using WHO
World Standard Population.17 For hypertension awareness
and treatment the analysis was done on the subpopulation
of hypertensive patients; for hypertension control, analysis
was done on the subpopulation of treated people. As there
were no national data available for these two subpopula-
tions for the purpose of weighting, at this stage of analysis,
we did not weigh the data. Prevalence rates were com-
pared using χ2 analysis and risk ratio (RR).16 When appro-
priate, test of hypothesis was done at significance level 0.05
two-sided. Associations between socio-demographic,
anthropometric and clinical factors and the prevalence of
hypertension were explored with logistic regression ana-
lysis, the diagnosis of hypertension being entered as a
dependent dichotomic variable. Results of regression ana-
lysis are expressed as RR with 95% Cl for each independ-
ent variable.18 All analyses were performed with SPSS
software, V.17.0 (SPSS).
RESULTS
Characteristics of study population
Characteristics of HYDY participants are reported in
table 1. Distribution among age decades and living loca-
tion (urban and rural) were identical among men and
women. Overall, the prevalence of illiterate subjects was
higher in women (51%) than in men (19%). The preva-
lence of obesity and abdominal obesity were also higher
in women (13.4%; 95% Cl 12.5% to 14.4%; and 26.5%;
95% Cl 25.3% to 27.7%) than in men (6.9%; 95% Cl
6.2% to 7.6%; and 3.4%; 95% Cl 2.9% to 3.9%).
All subjects received two visits at home separated by a
median interval of 5.36 days (95% Cl 5.30% to 5.42%;
range 1–13 days), with no differences between gender.
The average of the last two of the three BP and heart
rate readings taken at each visit is reported in table 1.
Values measured at visit 2 were lower than values
obtained at visit 1 both in men and in women.
Hypertension rate and diagnostic criteria
Overall, the rate of hypertension at visit 1 was 19.1%
(95% Cl 18.3% to 19.8%), being 15.9% (95% Cl 15.2%
to 16.6%) at visit 2. In particular 1307 and 7930 partici-
pants were found to be hypertensive and normotensive at
both visits, respectively; 642 subjects had an hypertension
diagnosis at visit 1 only, whereas 317 were hypertensive at
visit 2 only (χ2 test p<0.001). Therefore, when the diagno-
sis was based on fulfilling the same criteria on both visits
the estimated hypertension rate was lowered by 33%
(12.8%; 12.1% to 13.4%). When data were standardised
to the Yemen population (15–69 years) prevalence was
7.7% (95% CI 7.2% to 8.1%). This value, considering
both the visits, is lower than estimations obtained when
visit 1 (12.8%; 95% CI 12.2% to 13.4%) or visit 2 (10.5%;
95% CI 9.9% to 11%) are considered independently
(figure 1). Hypertension prevalence age-standardised to
the WHO world population 2001 aged 15–69 years was
11.3% (10.7% to 11.9%) when based on both visits and
17.3% (16.5% to 10%) when based on the first visit
(gender-specific values are reported in table 2).
Overall 528 subjects were on antihypertensive treat-
ment. Rates of awareness and treatment importantly
varied according to the criteria adopted for hypertension
diagnosis being higher when based on the results of both
visits. The estimation of control rates was more restrictive
when based on the result of both visits than of single visits
(table 2). In both genders the proportion of hypertensive
subjects aware of their hypertension, the proportion of
subjects under current treatment increased with age.
Conversely, as expected, the proportion of treated
subjects whose hypertension was controlled decreased
with age (table 2). When excluding individuals already
on antihypertensive drug treatment and estimating
hypertension prevalence on BP measurements, the rate
of hypertension among participants was 17.2% (16.4% to
18%) at visit 1 (n=1425), 12.8% (12.1% to 13.5%) at
visit 2 (n=1098), 8.7% (8.1% to 9.3%) of subjects (n=779)
fulfilling the criteria at both visits.
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Factors affecting misclassification of hypertension
at visit one
When considering untreated subjects, 53% of the 1094
participants who had hypertension grade 1 at the first
visit, and 24% of the 239 subjects with hypertension
grade 2, did not fulfil the criteria for hypertension at visit
2 reassessment. Conversely, only 8% of the 92 untreated
participants with grade 3 hypertension had normal BP
values at visit 2 reassessment. Misclassification also varied
by subject age. The younger the subjects were, the wider
Table 1 Characteristics of Hypertension and Diabetes in Yemen study participants
Men Women
Participants, n 5063 5179
Living in urban location, n (%) 2519 (49.8) 2590 (50.0)
Age (years), mean (95% Cl) 39.4 (39.0 to 39.9) 39.2 (38.7 to 39.6)
15–24 years, n (%) 1016 (20.1) 1058 (20.4)
25–34 years, n (%) 1020 (20.1) 1047 (20.2)
35–44 years, n (%) 1008 (19.9) 1021 (19.7)
45–54 years, n (%) 990 (19.6) 1057 (20.4)
55–69 years, n (%) 1029 (20.3) 996 (19.2)
Smokers (daily), n (%) 1428 (28.2) 458 (8.8)
Education (years), mean (95% Cl) 7.7 (7.5 to 7.9) 4.4 (4.2 to 4.5)
Illiterate, n (%) 986 (19.5) 2666 (51.5)
Can read and write, n (%) 830 (16.4) 375 (7.2)
Primary school, n (%) 685 (13.5) 661 (12.8)
Secondary school, n (%) 832 (16.4) 542 (10.5)
High school, n (%) 774 (15.3) 504 (9.7)
College or post, n (%) 950 (18.8) 428 (8.3)
Self-reported physical activity, n (%)
Sedentary 914 (21.1) 1465 (32.8)
Light to moderate 2606 (60.1) 2586 (57.9)
Vigorous 814 (18.8) 418 (9.4)
Self-reported fruit consumption, n (%)
≤1 day/week 2357 (46.7) 2470 (47.8)
2–4 day/week 1947 (38.6) 1962 (37.9)
≥5 days/week 744 (14.7) 740 (14.3)
Self-reported vegetable consumption, n (%)
≤1 day/week 1101 (21.8) 1040 (20.1)
2–4 day/week 1362 (26.9) 1437 (27.8)
≥5 days/week 2597 (51.3) 2692 (52.1)
Treated with antihypertensive drugs, n 215 313
Height (cm), mean (95% Cl) 161.6 (161.4 to 161.8) 153.1 to (152.9 to 153.3)
Weight (kg), mean (95% Cl) 60.5 (60.1 to 60.9) 56.9 (56.5 to 57.3)
Waist circumference (cm), mean (95% Cl) 78.5 (78.1 to 78.9) 80.0 (79.6 to 80.4)
Abdominal obesity, n (%) 171 (3.4) 1372 (26.5)
Body mass index (kg/m2), mean (95% Cl) 23.1 (22.9 to 23.3) 24.3 (24.1 to 24.5)
Overweight (25.0–29.9 kg/m2), n (%) 1174 (23.2) 1321 (25.5)
Obesity (≥30.0 kg/m2), n (%) 349 (6.9) 695 (13.4)
High cholesterol (≥5 mmol/l), n (%) 593 (11.7) 803 (15.5)
High triglycerides (≥1.7 mmol/l), n (%) 2007 (39.6) 1887 (36.4)
Diabetes 257 (5.1) 281 (5.4)
Interval between visits (days), mean (95% Cl) 5.2 (5.2 to 5.3) 5.5 (5.4 to 5.6)
First visit (mean, 95% Cl)
Systolic blood pressure (BP) (mm Hg) 123.0 (122.6 to 123.4) 122.7 (122.1 to 123.3)
Diastolic BP (mm Hg) 76.9 (76.5 to 77.3) 76.9 (76.7 to 77.1)
Heart rate (mm Hg) 79.3 (79.1 to 79.5) 2.2 (82.0 to 82.4)
Air temperature (°C) 24.4 (24.2 to 24.6) 24.3 (24.1 to 24.5)
Second visit (mean, 95% Cl)
Systolic BP (mm Hg) 121.5 (121.1 to 121.9) 120.6 (120.2 to 121.0)
Diastolic BP (mm Hg) 76.2 (76.0 to 76.4) 76.0 (75.8 to 76.2)
Heart rate (mm Hg) 78.5 (78.3 to 78.7) 81.1 (80.9 to 81.3)
Air temperature (°C) 24.4 (24.2 to 24.6) 24.2 (24.0 to 24.4)
Dipstik test ≥1+, n (%) 339 (6.7) 270 (5.2)
Self report of MI, stroke, POAD, n (%) 47 (0.9) 38 (0.7)
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the difference was between estimates based on one or
two visits (table 2). As a result, only 43% of men and 44%
of women <35 years of age found to be hypertensive at
visit one were hypertensive at both visits. These percen-
tages were 72% and 76% for men and women, respect-
ively, aged >45 years of age (table 3).
When characteristics of misclassified participants were
compared to untreated subjects with hypertension diag-
nosis confirmed at both visits (logistic regression analysis
including 1396 subjects), misclassification was found
to be independent by gender, education level, BMI and
W/H ratio tertiles. The probability to have the diagnosis
confirmed was directly associated with age decades, grade
of hypertension, provisional diagnosis of diabetes at visit
1 (FG≥7.0 mmol/l or self-reported use of hypoglycaemic
medications), and proteinuria ≥1+ at dipstick test.
Rates of proteinuria (≥1+ at dipstick test), or the self-
report of CV disease (MI, stroke and POAD) at question-
naire, were comparable among subjects classified as
hypertensive at the first, the second or at both visits
(table 3). However, the 959 participants found to be
hypertensive at visit 1 or at visit 2 only, and thus
excluded from the final diagnosis of hypertension (not
confirmed), had rates of proteinuria and self-reported
CV disease comparable with normotensive subjects (at
both visits) and the general population (table 4).
Cardiovascular risk stratification after one or two visits
BP readings taken at the first visit (SBP1/DBP1) or
average of BP readings taken at the first and the second
visits (SBP1–SBP2/DBP1–DBP2) were used to stratify
HYDY participants in the five BP categories according to
ESH/ESC guidelines.7 As indicated by figure 2 the dif-
ferent prevalence of hypertension when the diagnosis
rely on measurements taken at the first visit or at two
visits is mainly due to misclassification of subjects with
grade 1 hypertension.
CV risk stratification according to the ESH/ESC chart7
using average BP values at visit1 and at both visits is
reported in table 5. Most people had average or low
10-year CV risk, and a large fraction (84.3% after visit 1
and 86.2% after two visits) had CV risk <20% (average, low
or moderate). The age-weighted percentage of the popu-
lation with a CV risk ≥20% (high or very high CV risk) was
13.8% after visit 1 and 12% after two visits (table 5).
Overall, only 1.9% of Yemen population classified at high
or very high CV risk at visit 1 moved to average, low or
moderate CV risk categories after two visits (figure 3).
DISCUSSION
This study provides helpful results to clarify the impact
of survey strategy on the final estimation of hypertension
burden in developing countries. One of the major con-
tributions is the information that a strategy based on two
visits allows one to exclude from final diagnosis subjects
at low CV risk with a resultant 35% reduction of the esti-
mated prevalence of hypertension. This information is
essential for estimating drug costs and budget allocation
in national prevention programmes.
The fall in BP over repeated readings mainly rely to a
transient elevation of BP in persons submitted to BP
measurements, and was reported to be inversely related
with age and directly related to BP values.8 From a clin-
ical prospective, the uncertainty about the patient’s true
BP at clinic measurement may cause uncertainty in treat-
ment decisions.19 Therefore, guidelines for clinical prac-
tice commonly recommend that the diagnosis of
hypertension rely on multiple measurements obtained at
different visits.6 7 At the population level, the relevant
logistic difficulties and personnel costs of a strategy
based on two separate visits, and the negative prognostic
role of high BP variability and episodic hypertension,10
may sometimes lead to accept the adoption of a single
visit strategy. Ignoring the difference in hypertension
definition criteria may however lead to erroneous con-
clusions when comparing results of surveys assessing the
prevalence of hypertension, awareness and control in
different countries.20 In two epidemiological studies
where the estimation of hypertension prevalence based
on two visits was compared with the estimation based on
a single visit, the reduction was 12% in a cohort of
Figure 1 Diagnosis of
hypertension (systolic blood
pressure (BP) ≥140 mm Hg and/
or diastolic BP ≥90 mm Hg and/or
self-reported use of
antihypertensive drugs at the time
of the interview) performed on the
basis of measurements taken at
the first visit (visit 1), at the
second visit (visit 2) or both. The
number of subjects with and
without the condition and
age-weighted rates (to the
15–69 years Yemen population)
are reported.
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Table 2 Prevalence of hypertension, and awareness based on the first visit (visit 1), the second visit (visit 2) or both visits to the 10242 study participants
Hypertension Awareness among hypertensive subjects
Visit 1 Visit 2 Both Δ Visit 1 Visit 2 Both Δ
Men (n=5063)
Age decades, n (%)
15–24 years 48 (4.7) 42 (4.2) 15 (1.5) −68.1 4 (8.3) 4 (9.5) 4 (26.7) 220.0
25–34 years 82 (8.0) 68 (6.7) 41 (4.0) −50.0 13 (15.9) 13 (19.1) 13 (31.7) 100.0
35–44 years 142 (14.1) 101 (10.0) 73 (7.2) −48.6 20 (14.1) 20 (19.8) 20 (27.4) 94.5
45–54 years 263 (26.6) 234 (23.7) 188 (19.0) −28.7 85 (32.3) 85 (36.3) 85 (45.2) 39.9
55–69 years 375 (36.5) 315 (30.6) 272 (26.4) −27.5 118 (31.5) 118 (37.5) 118 (43.4) 37.9
Prevalence, % (95% Cl)
Crude 18.0 (16.9 to 19.1) 15.0 (14.0 to 16.0) 11.6 (10.8 to 12.5) −35.3 26.4 (23.7 to 29.4) 31.3 (28.1 to 34.7) 39.9 (36.0 to 43.9) 54.5
Age standardised* 16.2 (15.1 to 17.3) 13.5 (12.5 to 14.4) 10.2 (9.4 to 11.0) −37.0 – – – –
Women (n=5179)
Age decades, n (%)
15–24 years 56 (5.3) 40 (3.8) 17 (1.6) −69.7 1 (1.8) 1 (2.5) 1 (5.9) 229.4
25–34 years 97 (9.3) 68 (6.5) 46 (4.4) −52.6 16 (16.5) 16 (23.5) 16 (34.8) 110.9
35–44 years 163 (16.0) 136 (13.4) 105 (10.3) −35.6 54 (33.1) 54 (39.7) 54 (51.4) 55.2
45–54 years 371 (35.1) 325 (30.8) 285 (27.0) −23.2 138 (37.2) 138 (42.5) 138 (48.4) 30.2
55–69 years 356 (35.7) 297 (29.8) 265 (26.6) −25.6 133 (37.4) 133 (44.8) 133 (50.2) 34.3
Prevalence, % (95% Cl)
Crude 20.1 (19.1 to 21.2) 16.7 (15.7 to 17.8) 13.9 (12.9 to 14.8) −31.2 33.8 (31.0 to 36.8) 39.8 (36.6 to 43.1) 46.9 (43.3 to 50.6) 45.3
Age standardised* 18.3 (17.2 to 19.4) 15.1 (14.1 to 16.1) 12.3 (11.4 to 13.2) −32.8 – – – –
Δ=(percentage based on visit 1−percentage based on both visits)/percentage based on visit 1.
To the WHO standard population 2001.
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Table 3 Prevalence of treatment and control based on the first visit (visit 1), the second visit (visit 2), or both visits to the 10 242 study participants
Current treatment among hypertensive subjects Blood pressure control among treated subjects
Visit 1 Visit 2 Both Δ Visit 1 Visit 2 Both Δ
Men (n=5063)
Age decades, n (%)
15–24 years 3 (6.3) 3 (7.1) 3 (20.0) 220.0 1 (33.3) 1 (33.3) 1 (33.3) –
25–34 years 10 (12.2) 10 (14.7) 10 (24.4) 100.0 3 (30.0) 2 (20.0) 0 (0.0) –
35–44 years 17 (12.0) 17 (16.8) 17 (23.3) 94.5 7 (41.2) 9 (52.9) 7 (41.2) –
45–54 years 73 (27.8) 73 (31.2) 73 (38.8) 39.9 19 (26.0) 23 (31.5) 14 (19.2) −26.3
55–69 years 112 (29.9) 112 (35.6) 112 (41.2) 37.9 19 (17.0) 33 (29.5) 15 (13.4) −21.1
Prevalence, % (95% Cl)
Crude 23.6 (20.9 to 26.5) 28.3 (25.2 to 31.6) 36.5 (32.7 to 40.5) 54.5 22.8 (17.7 to 28.8) 31.6 (25.8 to 38.1) 17.2 (12.8 to 22.6) −24.5
Women (n=5179)
Age decades, n (%)
15–24 years 1 (1.8) 1 (2.5) 1 (5.9) 229.4 0 (0.0) 0 (0.0) 0 (0.0) –
25–34 years 13 (13.4) 13 (19.1) 13 (28.3) 110.9 8 (61.5) 9 (69.2) 6 (46.2) −25.0
35–44 years 50 (30.7) 50 (36.8) 50 (47.6) 55.2 27 (54.0) 29 (58.0) 22 (44.0) −18.5
45–54 years 124 (33.4) 124 (38.2) 124 (43.5) 30.2 36 (29.0) 47 (37.9) 31 (25.0) −13.9
55–69 years 125 (35.1) 125 (42.1) 125 (47.2) 34.3 38 (30.4) 41 (32.8) 31 (24.8) −18.4
Prevalence, % (95% Cl)
Crude 30.0 (27.3 to 32.9) 36.1 (33.0 to 39.4) 43.6 (40.0 to 47.2) 45.3 34.8 (29.7 to 40.2) 40.3 (35.0 to 45.7) 28.7 (24.0 to 34.0) −17.4
Δ=(percentage based on visit 1—percentage based on both visits)/ percentage based on visit 1.
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subjects aged 62±11 years,9 being >35% in a cohort of
subjects aged 39±9 years.18 In particular, two-thirds of
men <30 years of age had normal BP values at the
second visit.18 In both studies, the majority of subjects
misclassified as hypertensive were in the less severe
hypertensive grade.9 18 In a recent small survey the esti-
mation of hypertension prevalence had, as expected, a
strong association with the presence of left ventricular
hypertrophy independently from diagnostic criteria
(one or two visits).9 However, the most critical issue, the
CV risk of subjects excluded from final diagnosis, is still
poorly investigated. This information is especially crucial
in low resource setting where budget allocation to CV
prevention programmes might compete with other pri-
orities. HYDY study participants were stratified by cardio-
vascular risk according to ESH/ESC criteria7 thus
allowing one to investigate characteristics of misclassified
subjects. Subjects misclassified at first visit most fre-
quently belonged to low or moderate CV risk categories,
having a rate of proteinuria comparable to the general
population and to subjects found to be normotensive at
both visits. This does not necessarily imply that subjects
with high BP at both visits are ‘real’ hypertensives but
that they are higher-risk hypertensives. Therefore, when
resources are limited the estimation of hypertension
prevalence might be based on only one visit, while
resources can be more efficiently used to target high-risk
people who will benefit the most.
Heart attack and stroke are preventable either through
conventional management of single risk factors (hyper-
tension), or by applying a total CV risk approach which
could permit providers to focalise drug treatment use
only in high-risk subjects. CV risk has a continuous rela-
tionship with BP values. In particular, the present study
clarifies that although there is a large discrepancy (35%)
in the estimation of hypertension prevalence on the basis
of one visit or two visits, only 1.9% of the Yemen popula-
tion classified at high or very high CV risk at visit 1 moved
to average, low or moderate CV risk categories after two
visits. Current treatment strategies are indeed based on
CV risk stratification. It is recommended that pharmaco-
logical treatment should be provided for all people when
their calculated 10-year CV risk is at least 30% or more.
The risk threshold can be lowered to 20% if and when
resources permit. More precisely, age-weighted preva-
lence of subjects at very high CV risk estimated after
Figure 2 Factors associated
with confirmation of hypertension
diagnosis (systolic blood pressure
(BP) ≥140 mm Hg and/or diastolic
BP ≥90 mm Hg at both visits) at
multiple logistic regression
analysis including only
non-treated subjects (n=1396).
Results are expressed as OR
with 95% Cl.
Table 4 Rates of proteinuria and self-reported cardiovascular (CV) disease in Hypertension and Diabetes in Yemen
participants found to be hypertensive at visit 1, at visit 2 or at both visits, in subjects finally excluded from the final diagnosis
of hypertension (not confirmed), in normotensive subjects and in all participants
Diagnosis
Subjects DIPSTIK test ≥1+ Self-report of CV disease
n n % (95% Cl) n % (95% Cl)
Hypertension at visit 1 1938 153 7.9 (6.8 to 9.2) 58 3.0 (2.3 to 3.8)
Hypertension at visit 2 1614 141 8.7 (7.5 to 10.2) 55 3.4 (2.6 to 4.4)
Hypertension at both 1296 123 9.5 (8.0 to 11.2) 53 4.1 (3.1 to 5.3)
Not confirmed 959 48 5.0 (3.8 to 6.6) 7 0.7 (0.0 to 1.5)
Normotensives 7769 438 5.6 (5.1 to 6.2) 25 0.3 (0.2 to 0.5)
All participants 10 025 609 6.1 (5.6 to 6.6) 85 0.8 (0.7 to 1.0)
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one visit did not differ versus the estimation based on the
two visits strategy. A mild difference is appreciable only
when the 20% threshold is adopted, corresponding to
an estimated number of 227 000 Yemen patients aged
15–69 years.
The age-standardised prevalence of hypertension at first
visit for subjects aged 15–69 years (16.2%) is markedly
lower than rates reported in economically developed
countries for subjects older than 20 years (37.3%).2 Most
importantly, direct age standardisation to the 35–69 years
WHO World Standard Population17 (26.6%; 25.5% to
27.6%), allows comparison with Egypt (33.8%),21 Iran
(34.1%)22 or Turkey (34.2%).23 The low prevalence of
hypertension, besides any methodological consideration,
might thus be related to the possibility that Yemen is
behind in the epidemiological transition currently ongoing
in other countries of the Middle East Crescent area.
In conclusion, according to present data, the choice
of one or two visits strategy is not relevant, but it is
important to implement a strategy that allows for a more
comprehensive framework of CV risk.
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Table 5 Cardiovascular risk distribution among the 9926 adult subjects investigated in the Hypertension and Diabetes in
Yemen study based on the results first visit (visit 1), or both visits
After visit 1 After two visits Δ
Risk categories n= Crude (%) Age weighted, % (95% Cl) n Crude Age weighted, % (95% Cl) n
Average 2246 22.6 30.3 (28.9 to 31.6) 2326 23.4 31.3 (29.9 to 32.7) 128 851
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Δ=estimated difference between Yemen subjects attributed to the risk category on the basis of blood pressure (BP) measurements taken at
the first visit and those attributed to the same class on the basis of average of BP measurements taken at both visits (subjects allocated at
visit 1−subjects allocated after two visits).
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